Phase 2 N=16 Puerarin Effects on Alcohol Drinking
Alcohol Abuse
Primary: Amount of Alcohol Consumed — 3.46; 2.36 Number of drinks consumed
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=91 Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Ovarian Carcinoma · Breast Cancer
Primary: Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines — 75; 30.77; 0; 25.58 Percentage of participants
Phase 2 N=80 Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change From Baseline to Week 12 in Schirmer Test (ST) Score in Millimeters — 1.25; 3.81 Millimeters — p=0.027
Phase 2 N=48 Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
High Blood Pressure · Metabolic Syndrome · Insulin Resistance
Primary: Mean Change in Endothelial Function as Measured by Myocardial Blood Flow (MBF) From Baseline and After 12 Weeks of Treatment — 0.06; 0.12 mL/g/min
Phase 2 N=110 Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults
Influenza
Primary: Categorical Summary of Pain or Other Discomfort Immediately After Vaccination and on Days 3 and 7 Post-vaccination — 85; 75; 4; 2 Participants
Phase 2 N=490 Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder
Major Depressive Disorder
Primary: Montgomery and Åsberg Depression Rating Scale (MADRS) — -13.4; -19.0; -18.5; -19.4 Scores on a scale — p=0.6405
Phase 2 N=100 Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
Neoplasms, Breast
Primary: Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy — 54.0; 45.0; 74.0 percentage of participants
Phase 2 N=807 Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
Influenza · Orthomyxovirus Infection · Myxovirus Infection
Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions After Fluzone Intradermal or Fluzone Intramuscular or Fluzone High-dose Vaccine…
Phase 2 N=183 Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: Fasting Plasma Glucose at Baseline — 170.2; 168.2 mg/dL
Phase 2 N=1,248 Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions After Vaccination With Fluzone Intradermal or Fluzone Intramuscular Vaccine — 412; 54…
Phase 2 N=20 A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
Nasopharyngeal Cancer
Primary: Progression Free Survival. — 6.3 Months
Phase 2 N=254 Docetaxel and Oxaliplatin in Gastric Cancer
Stomach Neoplasms
Primary: Time to Progression — 4.50; 7.66; 5.55 Months
Phase 2 N=54 Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
Colorectal Cancer · Nausea and Vomiting
Primary: Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy. — 54 Participants
Phase 2 N=54 Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
Fever · Sweating · Hot Flashes
Primary: Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin. — 16 participants
Phase 2 N=41 O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
Brain and Central Nervous System Tumors
Primary: Percentage of Participants With an Objective Response (Complete Response or Partial Response) — 4; 0 Percent of Participants